Neuropeptide Y inhibits estrous behavior and stimulates feeding via separate receptors in Syrian hamsters.
Central injections of neuropeptide Y (NPY) increase food intake in Syrian hamsters; however, the effect of NPY on sexual behavior in hamsters is not known nor are the receptor subtypes involved in feeding and sexual behaviors. We demonstrate that NPY inhibits lordosis duration in a dose-related fashion after lateral ventricular injection in ovariectomized, steroid-primed Syrian hamsters. Under the same conditions, we compared the effect of two receptor-differentiating agonists derived from peptide YY (PYY), PYY-(3-36) and [Leu(31),Pro(34)]PYY, on lordosis duration and food intake. PYY-(3-36) produced a 91% reduction in lordosis duration at 0.24 nmol. [Leu(31),Pro(34)]PYY was less potent, producing a reduction in lordosis duration (66%) only at 2.4 nmol. These results suggest NPY effects on estrous behavior are principally mediated by Y2 receptors. PYY-(3-36) and [Leu(31),Pro(34)]PYY stimulated comparable dose-related increases in total food intake (2 h), suggesting Y5 receptors are involved in feeding. The significance of different NPY receptor subtypes controlling estrous and feeding behavior is highlighted by results on expression of Fos immunoreactivity (Fos-IR) elicited by either PYY-(3-36) or [Leu(31),Pro(34)]PYY at a dose of each that differentiated between the two behaviors. Some differences were seen in the distribution of Fos-IR produced by the two peptides. Overall, however, the patterns of expression were similar. Our behavioral and anatomic results suggest that NPY-containing pathways controlling estrous and feeding behavior innervate similar nuclei, with the divergence in pathways controlling the separate behaviors characterized by linkage to different NPY receptor subtypes.
Center for Neuroendocrine Studies, Neuroscience and Behavior Program and Department of Psychology,, Box 37720, University of Massachusetts-Amherst, Amherst, MA 01003, USA. escorp@psych.umass.edu
E S
ES
Corp
B
B
Gréco
J B
JB
Powers
C L
CL
Marín Bivens
G N
GN
Wade
D000704:Analysis of Variance; D000818:Animals; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D004971:Estrus / Q000502:physiology*; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D008647:Mesocricetus; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000494:pharmacology*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D019894:Peptide YY / Q000008:administration & dosage / Q000494:pharmacology; D011187:Posture; D016548:Prosencephalon / Q000187:drug effects / Q000502:physiology; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D013329:Structure-Activity Relationship
D009478:Neuropeptide Y; D010446:Peptide Fragments; D016760:Proto-Oncogene Proteins c-fos; C113547:neuropeptide Y (3-36); D019894:Peptide YY